Antisense modulation of CD36L1 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorKenneth W. Dobie
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of CD36L1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD36L1. Methods of using these compounds for modulation of CD36L1 expression and for treatment of diseases associated with expression of CD36L1 are provided.
Claims20
A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding CD36L1, wherein said compound specifically hybridizes with said nucleic acid molecule encoding CD36L1 and inhibits the expression of CD36L1.
A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding CD36L1.
Dependencies are inferred from the claim text.